List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 25 studies with search of: Open Studies | "Pheochromocytoma"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma;   Essential Hypertension
Interventions: Other: plasma EM66 & CgA levels assessment;   Other: usual follow up with regular EM66 & Cga levels assessment
2 Recruiting Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Drug: Sunitinib
3 Recruiting Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
Conditions: Extra-adrenal Paraganglioma;   Paraganglioma;   Pheochromocytoma
Interventions: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
4 Recruiting Diagnosis of Pheochromocytoma
Condition: Pheochromocytoma
Intervention:
5 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
6 Recruiting RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Conditions: Pheochromocytoma;   Extra-Adrenal Paraganglioma;   Non-functioning Carcinoid
Intervention: Drug: RAD001
7 Unknown † Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention:
8 Unknown † Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Conditions: Neuroblastoma;   Pheochromocytoma
Intervention: Radiation: iobenguane I 131
9 Recruiting 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma (Relapsed or Refractory);   Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG);   Drug: 131 I-MIBG
10 Recruiting First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Condition: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
Interventions: Drug: Sunitinib;   Drug: Placebo
11 Recruiting Phenoxybenzamine Versus Doxazosin in PCC Patients
Condition: Pheochromocytoma
Interventions: Drug: Phenoxybenzamine;   Drug: Doxazosin
12 Recruiting Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low- or Intermediate-Grade Neuroendocrine Cancer
Conditions: Extra-Adrenal Paraganglioma;   Gastrointestinal Carcinoid Tumor;   Head and Neck Cancer;   Islet Cell Tumor;   Lung Cancer;   Neuroendocrine Carcinoma of the Skin;   Pheochromocytoma
Interventions: Biological: cixutumumab;   Drug: everolimus;   Drug: octreotide acetate;   Other: laboratory biomarker analysis;   Other: pharmacological study
13 Unknown † Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neuroblastoma;   Pheochromocytoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: yttrium Y 90-edotreotide
14 Recruiting Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma
Condition: Pheochromocytoma
Intervention:
15 Unknown † Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Procedure: diagnosis methods
16 Not yet recruiting 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Conditions: Pheochromocytoma;   Neuroblastoma;   Paraganglioma;   Medullary Thyroid Carcinoma;   Carcinoid Tumors
Intervention: Drug: 123I-meta-iodobenzylguanidine
17 Recruiting Adrenal Tumors - Pathogenesis and Therapy
Conditions: Adrenal Tumors;   Adrenocortical Carcinoma;   Cushing Syndrome;   Conn Syndrome;   Pheochromocytoma
Intervention:
18 Unknown † Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Conditions: Von Hippel-Lindau Disease;   Hemangioblastoma;   Renal Cell Carcinoma;   Pheochromocytoma;   Pancreatic Neuroendocrine Tumor
Intervention: Other: 89Zr bevacizumab PET scan
19 Unknown † Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot
Condition: Chromaffin-tissue Derived Tumors
Intervention: Other: Scintigraphy in 123I-IBZM
20 Recruiting RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: RAD001;   Drug: erlotinib

Previous Page Studies Shown (1-20) Next Page (21-25)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services